文献速递淋巴瘤白血病

hyper-CVAD-R方案治疗伯基特白血病/淋巴瘤及高级别B细胞淋巴瘤的长期结局:聚焦中枢神经系统复发

Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse.
PubMed 文献 · Blood Adv · 2021-01-01

该研究报告了hyper-CVAD-R方案在79例成人伯基特白血病/淋巴瘤(BL)及高级别B细胞淋巴瘤(HGBL)患者中的长期安全性和疗效,重点关注预防中枢神经系统(CNS)复发。中位年龄44岁,73%有骨髓受累,28%有CNS受累。完全缓解率91%,5年无复发生存率和总生存率分别为58%和52%。5年CNS累积复发率为6%,基线CNS受累者为16%。数据支持hyper-CVAD-R用于预防CNS复发,尤其在高危骨髓或CNS受累患者中。

要点

  • hyper-CVAD-R方案在BL/HGBL中完全缓解率达91%,5年RFS和OS分别为58%和52%。
  • 年龄和CNS受累是OS和RFS的独立预测因素。

核心结论

  • hyper-CVAD-R方案可有效预防BL和HGBL患者的CNS复发,尤其在高危骨髓或CNS受累患者中。

研究设计与样本

  • 报告79例成人BL(54例)和HGBL(25例)患者接受hyper-CVAD-R方案的长期安全性和疗效,中位年龄44岁(25%≥60岁)。

主要发现

  • 5年无复发生存率和总生存率分别为58%和52%。
  • 多因素分析中,年龄和CNS受累是OS和RFS的独立预测因素。

临床怎么用

  • 对于BL和HGBL患者,尤其存在骨髓或CNS受累的高危患者,可考虑使用hyper-CVAD-R方案以预防CNS复发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Burkitt leukemia/lymphoma (BL) and high-grade B-cell lymphoma (HGBL) have a high incidence of central nervous system (CNS) involvement, which is associated with poor prognosis. The hyper-cyclophosphamide, vincristine, Adriamycin, and dexamethasone plus rituximab (CVAD-R) regimen includes systemic and intrathecal CNS-directed therapy to treat and prevent CNS disease. We report here the long-term safety and efficacy of the hyper-CVAD-R regimen in adults with BL and HGBL, focusing on its efficacy to prevent CNS relapse. Among 79 adults (54 BL, 25 HGBL), the median age was 44 years (25% ≥60 years old), 73% had bone marrow (BM) involvement, and 28% had CNS involvement. The complete response rate was 91% (BL 96%; HGBCL 79%; P = .16). The 5-year relapse-free survival (RFS) and overall survival (OS) rates were 58% and 52%, respectively. The cumulative incidence of relapse (CIR) was 21% (BL 14%; HGBCL 37%, P = .06) and was associated with baseline BM (27% vs 0%; P = .02) and CNS (42% vs 12%; P < .01) involvement. In multivariate analyses, age and CNS involvement were independent predictors for OS and RFS. The 5-year CNS CIR was 6% (BL 4%; HGBL 11%; P = .31); 16% with baseline CNS involvement (P = .03). Our data support the use of hyper-CVAD-R in preventing CNS relapse, especially among high-risk patients with BM or CNS involvement.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Samra B, Khoury JD, Morita K, et al. Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse. Blood Adv. 2021. PMID: 34464974. doi:10.1182/bloodadvances.2021004427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。